The co-existence of BRAFmutant and NRASmutant tumor cells has potential clinical implications as in-vitro studies have demonstrated that pharmacologic inhibition of wild-type BRAF in the presence of oncogenic RAS can promote melanoma proliferation and/or resistance to apoptosis [34], [35], [36], [37], [38], [39]. This evidence concerns the gene BRAF and melanoma.